Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 2/20 | 0.55 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.55 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.55 |
| ▸ | EIF2AK4 | Q9P2K8 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 8/20 | 0.40 |
| ▸ | JAK3 | P52333 | 7/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 2/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.38 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 3/20 | 0.38 |
| ▸ | KIT | P10721 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12616691 | 0.90 | NTRK1 (0.46) | NTRK1NTRK3NTRK2EIF2AK4CYP1A2 | |
| SCHEMBL2039268 | 0.83 | NTRK1 (0.42) | NTRK1NTRK3NTRK2EIF2AK4KIT | |
| SCHEMBL2040961 | 0.81 | NTRK1 (0.38) | NTRK1NTRK3NTRK2EIF2AK4CYP1A2 | |
| SCHEMBL2000446 | 0.78 | KIT (0.60) | NTRK1NTRK3NTRK2EIF2AK4CYP1A2 | |
| SCHEMBL1994074 | 0.74 | EIF2AK4 (0.49) | EIF2AK4CYP3A4JAK2JAK3FLT3 | |
| SCHEMBL21194708 | 0.73 | EIF2AK4 (0.48) | EIF2AK4JAK2JAK3FLT3IRAK4 | |
| SCHEMBL1993988 | 0.73 | EIF2AK4 (0.48) | EIF2AK4CYP3A4JAK2JAK3FLT3 | |
| SCHEMBL1992453 | 0.72 | IRAK4 (0.51) | EIF2AK4JAK2JAK3FLT3IRAK4 | |
| SCHEMBL1992451 | 0.72 | IRAK4 (0.51) | EIF2AK4JAK2JAK3FLT3IRAK4 | |
| SCHEMBL1997445 | 0.72 | EIF2AK4 (0.43) | EIF2AK4JAK2JAK3FLT3IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | claimed |
| EP-2516436-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2012-10-31 | — | — | EP | claimed |
| WO-2011076419-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-30 | — | — | WO | claimed |
| EP-2338888-A1 | Imidazopyridine derivatives as JAK inhibitors | Almirall, S.A. (ES) | 2011-06-29 | — | — | EP | claimed |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| EP-2516436-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011076419-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011076419-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-30 | — | — | WO | disclosed |
| EP-2338888-A1 | Imidazopyridine derivatives as JAK inhibitors | Almirall, S.A. (ES) | 2011-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | NTRK1 2746/4885NTRK3 2092/4885NTRK2 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.